

Human TNFSF14 / LIGHT / CD258 Protein (Fc Tag)

Catalog Number: 10386-H04H5



Sino Biological
Biological Solution Specialist

General Information

Gene Name Synonym:

CD258; HVEM; LIGHT; LTg; TR2

Protein Construction:

A DNA sequence encoding the human TNFSF14 (AAK26160.1) (Asp74-Val240) was expressed with the Fc region of mouse IgG1 at the N-terminus.

Source: Human

Expression Host: HEK293 Cells

QC Testing

Purity: > (86.1±5.7) % as determined by SDS-PAGE.

Endotoxin:

< 1.0 EU per µg protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Asp

Molecular Mass:

The recombinant human TNFSF14 consists of 403 amino acids and predicts a molecular mass of 44.9 kDa.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble nonsignaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.

References

- 1.Ogawa T, *et al.* (2010) CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. *J Urol.* 183(3): 1206-12.
- 2.Kanodia S, *et al.* (2010) Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. *Cancer Res.* 70(10): 3955-64.
- 3.Hosokawa Y, *et al.* (2010) TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN-gamma-stimulated human gingival fibroblasts. *Mol Immunol.* 47(4): 666-70.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>